Status:
COMPLETED
Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI
Lead Sponsor:
ConBio, a Cynosure Company
Conditions:
Acne Scars
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the RevLite Q-Switched Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) Laser in the treatment of acne scars in darker skin types (Fitzpatrick Skin Types III, IV, V...
Eligibility Criteria
Inclusion
- 18 years or older with Fitzpatrick Skin Type III, IV, V or VI
- Evidence of atrophic scarring
Exclusion
- Pregnancy, lactating or planning to become pregnant during the study
- History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
- Any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
- Any condition which, in the investigator's opinion, would make it unsafe for the subject to participate
- Currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering the study
- Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
- Subject may be unreliable for the study. This includes subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
- Use of oral or topical isotretinoin therapy within 6 months prior to enrollment. With the exception of isotretinoin, subjects will be allowed to continue their topical or oral acne medications during the trial
- Need to be exposed to artificial tanning devices or excessive sunlight during the trial
- Prior treatment with parenteral gold therapy
- Diabetes Type I or II, Lupus, Scleroderma or a similar immune system disorder
- Subject does not agree to refrain from any other type of facial skin resurfacing (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected filler/other substances (e.g., Restylane, Botox) that might affect the treatment area for the duration of the study
- Underlying silicone or other nonabsorbable fillers in the treatment area or has had filler (e.g., collagen, fat) injections within the past 3 months
- History of keloidal scarring or nodulocystic acne
- Phenol or chemical peel or dermabrasion to the the treatment area within the past 6 months
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01221922
Start Date
October 1 2010
End Date
January 1 2012
Last Update
November 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasemrad Aesthetic Center, Kasemrad Prachacheun Hospital
Bangkok, Thailand